IL25513A - Method and means of determining endpoint times in blood clotting tests - Google Patents
Method and means of determining endpoint times in blood clotting testsInfo
- Publication number
- IL25513A IL25513A IL25513A IL2551366A IL25513A IL 25513 A IL25513 A IL 25513A IL 25513 A IL25513 A IL 25513A IL 2551366 A IL2551366 A IL 2551366A IL 25513 A IL25513 A IL 25513A
- Authority
- IL
- Israel
- Prior art keywords
- time
- plasma
- differential
- signal
- timer
- Prior art date
Links
- 238000012360 testing method Methods 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 24
- 230000023555 blood coagulation Effects 0.000 title claims 4
- 108010094028 Prothrombin Proteins 0.000 claims description 35
- 102100027378 Prothrombin Human genes 0.000 claims description 35
- 229940039716 prothrombin Drugs 0.000 claims description 35
- 230000003287 optical effect Effects 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 description 24
- 230000035602 clotting Effects 0.000 description 16
- 206010053567 Coagulopathies Diseases 0.000 description 11
- 239000003990 capacitor Substances 0.000 description 11
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 6
- 108010000499 Thromboplastin Proteins 0.000 description 6
- 102000002262 Thromboplastin Human genes 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 239000004020 conductor Substances 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
- G01N21/272—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration for following a reaction, e.g. for determining photometrically a reaction rate (photometric cinetic analysis)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Ecology (AREA)
- Mathematical Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45188565A | 1965-04-29 | 1965-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL25513A true IL25513A (en) | 1970-10-30 |
Family
ID=23794095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL25513A IL25513A (en) | 1965-04-29 | 1966-04-01 | Method and means of determining endpoint times in blood clotting tests |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3458287A (enrdf_load_stackoverflow) |
| BE (1) | BE680369A (enrdf_load_stackoverflow) |
| CH (1) | CH446768A (enrdf_load_stackoverflow) |
| DE (1) | DE1598788C3 (enrdf_load_stackoverflow) |
| GB (1) | GB1136257A (enrdf_load_stackoverflow) |
| IL (1) | IL25513A (enrdf_load_stackoverflow) |
| NL (1) | NL6605865A (enrdf_load_stackoverflow) |
| SE (1) | SE327575B (enrdf_load_stackoverflow) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3520609A (en) * | 1966-07-21 | 1970-07-14 | Pfizer & Co C | Method and apparatus for detecting agglutination reactions |
| US3807878A (en) * | 1967-07-27 | 1974-04-30 | L Fields | Optical densitometer for indicating the optical density and rate of change of the optical density of a specimen |
| US3593568A (en) * | 1969-04-01 | 1971-07-20 | Bio Dynamics Inc | Prothrombin time measuring apparatus with means to start the timer in response to the initial decrement of optical transmissivity |
| US3658480A (en) * | 1970-04-13 | 1972-04-25 | Bio Data Corp | Coagulation timing apparatus, and method |
| JPS5640789B1 (enrdf_load_stackoverflow) * | 1971-05-12 | 1981-09-24 | ||
| US3765841A (en) * | 1971-08-06 | 1973-10-16 | Beckman Instruments Inc | Method and apparatus for chemical analysis |
| US4047890A (en) * | 1973-11-01 | 1977-09-13 | Bio/Data Corporation | Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas |
| JPS5125191A (ja) * | 1974-08-26 | 1976-03-01 | Nippon Kogaku Kk | Kosohannosokudosokuteisochi |
| US4101276A (en) * | 1976-06-02 | 1978-07-18 | Beckman Instruments, Inc. | Method and apparatus for signalling the introduction of chemical reaction components into a chemical analyzing system |
| US4097238A (en) * | 1977-06-03 | 1978-06-27 | Ashley Sheldon J | Method of analyzing blood plasma clotting |
| JPS5451893A (en) * | 1977-09-30 | 1979-04-24 | Sankyo Co | Measuring of blood coagulating time |
| JPS5469497A (en) * | 1977-11-12 | 1979-06-04 | Kyoto Daiichi Kagaku Kk | Method and device for measuring blood solidification time |
| JPS5822703B2 (ja) * | 1978-08-30 | 1983-05-10 | 三共株式会社 | 血液凝固測定方法 |
| IT1105662B (it) * | 1978-09-07 | 1985-11-04 | Salus Istituto Diagnostico Di | Apparecchiatura per studiare e fenomeni della emocoagulazione e dell'aggregazione delle piastrine |
| AU4158785A (en) * | 1984-03-26 | 1985-11-01 | International Health Services | A method of determining the clotting time of blood and particulate reagents therefor |
| ATE92630T1 (de) * | 1984-06-27 | 1993-08-15 | Wako Pure Chem Ind Ltd | Geraet zur messung von endotoxin. |
| US5114860A (en) * | 1984-10-09 | 1992-05-19 | Toa Medical Electronics Co., Ltd. | Device of measuring a blood coagulating time |
| GB8426004D0 (en) * | 1984-10-15 | 1984-11-21 | Ortho Diagnostic Systems Inc | Coagulation monitoring |
| US5156974A (en) * | 1988-05-27 | 1992-10-20 | Biodata Corporation | Method for determining the fibrinogen level of a blood sample |
| US5169786A (en) * | 1989-12-19 | 1992-12-08 | Ortho Diagnostic Systems, Inc. | Method of determining levels of extrinsic and intrinsic clotting factors and protein c |
| US5167145B1 (en) * | 1990-09-19 | 2000-05-23 | David M Butler | Measurement of blood coagulation time using infrared electromagnetic energy |
| US5197017A (en) * | 1990-09-27 | 1993-03-23 | Carroll Wallace E | Potentiophotometric fibrinogen determination |
| DK203191D0 (da) * | 1991-12-19 | 1991-12-19 | Novo Nordisk As | Fremgangsmaade og apparat til bestemmelse af relevante blodparametre |
| US5708591A (en) * | 1995-02-14 | 1998-01-13 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions |
| US6429017B1 (en) | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| US6321164B1 (en) | 1995-06-07 | 2001-11-20 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade |
| US6898532B1 (en) | 1995-06-07 | 2005-05-24 | Biomerieux, Inc. | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
| US6069011A (en) * | 1997-12-10 | 2000-05-30 | Umm Electronics, Inc. | Method for determining the application of a sample fluid on an analyte strip using first and second derivatives |
| US6502040B2 (en) | 1997-12-31 | 2002-12-31 | Biomerieux, Inc. | Method for presenting thrombosis and hemostasis assay data |
| CN1309770A (zh) * | 1998-07-31 | 2001-08-22 | 华莱士·E·卡罗尔 | 确定抗凝治疗因子的设备和方法 |
| ATE282208T1 (de) * | 1999-02-04 | 2004-11-15 | Bio Merieux Inc | Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben |
| US7179612B2 (en) | 2000-06-09 | 2007-02-20 | Biomerieux, Inc. | Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality |
| US6706536B1 (en) | 2000-11-28 | 2004-03-16 | Wada, Inc. | Method and apparatus for processing coagulation studies, chemistry procedures and the like |
| JP2005527471A (ja) * | 2001-09-10 | 2005-09-15 | ザイモジェネティクス，インコーポレイティド | クマリン−誘発された出血を処理するための方法 |
| DE102007017906A1 (de) * | 2007-04-17 | 2008-10-23 | Dade Behring Marburg Gmbh | Verfahren zur Bestimmung der Reaktions-Lag-Phase in einer analytabhängigen Reaktion |
| US20130046293A1 (en) * | 2010-03-09 | 2013-02-21 | Keio University | System for preventing blood charring at laser beam emitting site of laser catheter |
| EP2982988B1 (en) * | 2013-04-02 | 2018-07-25 | Hitachi High-Technologies Corporation | Automatic analysis device and analysis method |
| RU2559986C1 (ru) * | 2014-09-26 | 2015-08-20 | Геннадий Григорьевич Мартюшов | Способ определения времени свёртывания крови и устройство для его осуществления |
| JP6952668B2 (ja) * | 2018-09-28 | 2021-10-20 | シスメックス株式会社 | 血液凝固分析方法、血液凝固分析装置、プログラム |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2878106A (en) * | 1955-06-08 | 1959-03-17 | E H Sargent & Co | Automatic differential potentiometric titrator |
| NL298730A (enrdf_load_stackoverflow) * | 1962-04-18 | |||
| US3307392A (en) * | 1964-05-04 | 1967-03-07 | Research Corp | Automatic prothrombin timer apparatus and method |
-
1965
- 1965-04-29 US US451885A patent/US3458287A/en not_active Expired - Lifetime
-
1966
- 1966-04-01 IL IL25513A patent/IL25513A/en unknown
- 1966-04-25 GB GB18002/66A patent/GB1136257A/en not_active Expired
- 1966-04-28 DE DE1598788A patent/DE1598788C3/de not_active Expired
- 1966-04-28 SE SE05794/66A patent/SE327575B/xx unknown
- 1966-04-29 BE BE680369D patent/BE680369A/xx unknown
- 1966-04-29 CH CH621966A patent/CH446768A/fr unknown
- 1966-04-29 NL NL6605865A patent/NL6605865A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH446768A (fr) | 1967-11-15 |
| GB1136257A (en) | 1968-12-11 |
| NL6605865A (enrdf_load_stackoverflow) | 1966-10-31 |
| SE327575B (enrdf_load_stackoverflow) | 1970-08-24 |
| DE1598788C3 (de) | 1974-06-20 |
| BE680369A (enrdf_load_stackoverflow) | 1966-10-03 |
| DE1598788B2 (de) | 1973-11-22 |
| US3458287A (en) | 1969-07-29 |
| DE1598788A1 (de) | 1971-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3458287A (en) | Method and means of determining endpoint times in blood clotting tests | |
| US4252536A (en) | Method and system for measuring blood coagulation time | |
| US3267364A (en) | Coagulation timer | |
| US3658480A (en) | Coagulation timing apparatus, and method | |
| US2977199A (en) | Method for the continuous testing of flowing materials | |
| US5981285A (en) | Method and apparatus for determining anticoagulant therapy factors | |
| Poggio et al. | The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents | |
| US5502651A (en) | Potentiophotometric fibrinogen determination | |
| US4047890A (en) | Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas | |
| US5197017A (en) | Potentiophotometric fibrinogen determination | |
| US4276383A (en) | Clot lysing timer | |
| CA1047788A (en) | Nephelometer having means semiautomatically cancelling components from scattering by particles smaller or larger than those of interest | |
| US4454752A (en) | Test circuit for use in coagulation instrument | |
| US4309112A (en) | Rate measurement analyzer | |
| US3786352A (en) | Rate analysis system with overrange signal detection circuit for identifying false signals | |
| US20100235103A1 (en) | Method and apparatus for evaluating prothrombotic conditions | |
| Bett et al. | An automatic coulometric titrimeter | |
| US20040219680A1 (en) | Method and apparatus for determining anticoagulant therapy factors | |
| US4297105A (en) | Automatic photometric titrator | |
| US3267363A (en) | Electrical apparatus for fiber detection | |
| EP1907866B1 (en) | Method and apparatus for determining anticoagulant therapy factors | |
| US3743424A (en) | Combined electronic and optical method and apparatus for analyzing liquid samples | |
| US5602468A (en) | Method and apparatus for ion chamber identification | |
| EP0062616A1 (en) | Method for studying blood coagulation and the aggregation of platelets in the blood, and device employed to carry out said method | |
| US7901694B2 (en) | Method and apparatus for determining anticoagulant therapy factors |